{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:46:28Z","timestamp":1762868788204,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/113014\/2015","UIDP\/00776\/2020","SFRH\/BD\/138670\/2018"],"award-info":[{"award-number":["SFRH\/BPD\/113014\/2015","UIDP\/00776\/2020","SFRH\/BD\/138670\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00384-022-04126-6","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T06:02:54Z","timestamp":1647583374000},"page":"895-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR"],"prefix":"10.1007","volume":"37","author":[{"given":"Manuela","family":"Pinheiro","sequence":"first","affiliation":[]},{"given":"Ana","family":"Peixoto","sequence":"additional","affiliation":[]},{"given":"Patricia","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Veiga","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Guerra","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Escudeiro","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Barbosa","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5982","authenticated-orcid":false,"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"4126_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"4126_CR2","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3:iii1\u20139","DOI":"10.1093\/annonc\/mdu260"},{"key":"4126_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26:13\u201321","journal-title":"Ann Oncol"},{"key":"4126_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/PAP.0b013e3181a9d4ed","volume":"16","author":"TP Plesec","year":"2009","unstructured":"Plesec TP, Hunt JL (2009) KRAS mutation testing in colorectal cancer. Adv Anat Pathol 16:196\u2013203","journal-title":"Adv Anat Pathol"},{"key":"4126_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883\u2013892","journal-title":"N Engl J Med"},{"key":"4126_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","volume":"25","author":"L De Mattos-Arruda","year":"2014","unstructured":"De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V et al (2014) Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 25:1729\u20131735","journal-title":"Ann Oncol"},{"key":"4126_CR7","doi-asserted-by":"crossref","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24","DOI":"10.1158\/1538-7445.AM2014-5606"},{"key":"4126_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/annonc\/mdv005","volume":"26","author":"MP Morelli","year":"2015","unstructured":"Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C et al (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26:731\u2013736","journal-title":"Ann Oncol"},{"key":"4126_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/1878-0261.12023","volume":"11","author":"W Schmiegel","year":"2017","unstructured":"Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H et al (2017) Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol 11:208\u2013219","journal-title":"Mol Oncol"},{"key":"4126_CR10","doi-asserted-by":"publisher","first-page":"8976","DOI":"10.1038\/s41598-019-45616-y","volume":"9","author":"A Vivancos","year":"2019","unstructured":"Vivancos A, Aranda E, Benavides M, \u00c9lez E, G\u00f3mez-Espa\u00f1a MA, Toledano M, Alvarez M, Parrado MRC, Garc\u00eda-Barber\u00e1n V, Diaz-Rubio E (2019) Comparison of the clinical sensitivity of the Idylla platform and the OncoBEAM RAS CRC assay for KRAS mutation detection in liquid biopsy samples. Sci Rep 9:8976","journal-title":"Sci Rep"},{"key":"4126_CR11","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.1133470100","volume":"100","author":"D Dressman","year":"2003","unstructured":"Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 100:8817\u20138822","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4126_CR12","doi-asserted-by":"publisher","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102:16368\u201316373","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4126_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouch\u00e9 O, Mineur L, Barone C et al (2015) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16:937\u2013948","journal-title":"Lancet Oncol"},{"key":"4126_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cancergen.2011.07.003","volume":"204","author":"P Pinto","year":"2011","unstructured":"Pinto P, Rocha P, Veiga I, Guedes J, Pinheiro M, Peixoto A, Pinto C, Fragoso M, Sanches E, Ara\u00fajo A et al (2011) Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet 204:439\u2013446","journal-title":"Cancer Genet"},{"key":"4126_CR15","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","volume":"28","author":"J Grasselli","year":"2017","unstructured":"Grasselli J, Elez E, Carat\u00f9 G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Vi\u00e9itez JM, Pa\u00e9z D et al (2017) Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 28:1294\u20131301","journal-title":"Ann Oncol"},{"key":"4126_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023\u20131034","journal-title":"N Engl J Med"},{"key":"4126_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12967-016-1053-z","volume":"14","author":"G Palomba","year":"2016","unstructured":"Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A et al (2016) Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. J Transl Med 14:292","journal-title":"J Transl Med"},{"key":"4126_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/bmm-2016-0358","volume":"11","author":"G Kafatos","year":"2017","unstructured":"Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, Traugottov\u00e1 Z, Bilalis A, Molnar E, Timar J et al (2017) RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomark Med 11:751\u2013760","journal-title":"Biomark Med"},{"key":"4126_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","volume":"28","author":"J Vidal","year":"2017","unstructured":"Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodr\u00edguez C, Brozos E et al (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28:1325\u20131332","journal-title":"Ann Oncol"},{"key":"4126_CR20","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s41416-018-0293-5","volume":"119","author":"J Garc\u00eda-Foncillas","year":"2018","unstructured":"Garc\u00eda-Foncillas J, Tabernero J, \u00c9lez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, L\u00f3pez R, Muinelo-Romay L, Montagut C et al (2018) Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer 119:1464\u20131470","journal-title":"Br J Cancer"},{"key":"4126_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41416-019-0457-y","volume":"120","author":"H Bando","year":"2019","unstructured":"Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H et al (2019) A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. Br J Cancer 120:982\u2013986","journal-title":"Br J Cancer"},{"key":"4126_CR22","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2217\/fon-2020-0523","volume":"16","author":"T Germetaki","year":"2020","unstructured":"Germetaki T, Nicholls C, Adams RA, Braun M, Rogan J, Moghadam S, Lenfert E, Lukas A, Edelstein DL, Jones FS et al (2020) Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncol 16:2177\u20132189","journal-title":"Future Oncol"},{"key":"4126_CR23","first-page":"1","volume":"6","author":"L Heuls","year":"2018","unstructured":"Heuls L, Staub NP, Iurisci I, Goyer P, Saget A, Richa H, Marijon H, Dainese L, Larsen AK, Gramont A et al (2018) Extended RAS mutational status analysis in circulating tumor DNA from patients with advanced colorectal cancer in daily clinical practice. The Franco-British Institute Experience and Recommendations. Biomed J Sci & Tech Res 6:1\u20136","journal-title":"Biomed J Sci & Tech Res"},{"key":"4126_CR24","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/cancers11101504","volume":"11","author":"PP Vitiello","year":"2019","unstructured":"Vitiello PP, De Falco V, Giunta EF, Ciardiello D, Cardone C, Vitale P, Zanaletti N, Borrelli C, Poliero L, Terminiello M et al (2019) Clinical practice use of liquid biopsy to identify RAS\/BRAF mutations in patients with metastatic colorectal cancer (mCRC): a single institution experience. Cancers (Basel) 11:1504","journal-title":"Cancers (Basel)"},{"key":"4126_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532\u2013536","journal-title":"Nature"},{"key":"4126_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr","year":"2012","unstructured":"Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537\u2013540","journal-title":"Nature"},{"key":"4126_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nm.3511","volume":"20","author":"AR Thierry","year":"2014","unstructured":"Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B et al (2014) Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20:430\u2013435","journal-title":"Nat Med"},{"key":"4126_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Rossini D, Dell\u2019Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G et al (2019) Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical Trial. JAMA Oncol 5:343\u2013350","journal-title":"JAMA Oncol"},{"key":"4126_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/CAD.0000000000000923","volume":"31","author":"E Lastraioli","year":"2020","unstructured":"Lastraioli E, Lavacchi D, Palmieri VE, Castiglione F, Messerini L, Di Costanzo F, Antonuzzo L (2020) Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. Anticancer Drugs 31:979\u2013982","journal-title":"Anticancer Drugs"},{"key":"4126_CR30","doi-asserted-by":"crossref","unstructured":"Franczak C, Witz A, Geoffroy K, Demange J, Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P et al (2020) Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer. PLoS One 15:e0227294","DOI":"10.1371\/journal.pone.0227294"},{"key":"4126_CR31","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1038\/s41598-020-64822-7","volume":"10","author":"DCL Vessies","year":"2020","unstructured":"Vessies DCL, Greuter MJE, van Rooijen KL, Linders TC, Lanfermeijer M, Ramkisoensing KL, Meijer GA, Koopman M, Coup\u00e9 VMH, Vink GR et al (2020) Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing. Sci Rep 10:8122","journal-title":"Sci Rep"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-022-04126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-022-04126-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-022-04126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T04:06:12Z","timestamp":1648872372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-022-04126-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4126"],"URL":"https:\/\/doi.org\/10.1007\/s00384-022-04126-6","relation":{},"ISSN":["1432-1262"],"issn-type":[{"type":"electronic","value":"1432-1262"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"2 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of IPO Porto (reference number CES 85\u2013017) and informed consent was taken from all individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}